Influx Healthtech Limited, a Mumbai-based contract development and manufacturing organization (CDMO) serving the healthcare sector, is hitting the primary market with its SME IPO on the NSE SME platform. The company specializes in providing tailored solutions across pharmaceuticals, nutraceuticals, and wellness product domains.

The IPO, worth ₹58.57 crore, consists of a fresh issue of ₹48 crore (50 lakh shares) and an offer for sale (OFS) of ₹10.57 crore (11 lakh shares) by existing shareholders.

IPO Timeline & Key Dates:

IPO Details:

Anchor Investment:

Influx Healthtech raised ₹16.66 crore from Anchor Investors by allotting 17,36,400 shares at the upper price band of ₹96.

Live Subscription Status (as of June 20, 2025):

The IPO witnessed blockbuster demand, especially from HNIs and institutional investors.

Company Overview:

Founded in 2020, Influx Healthtech Limited has quickly gained prominence in the healthcare sector. As a Contract Development and Manufacturing Organization (CDMO), the company serves clients across pharmaceuticals, personal care, wellness, and cosmetics industries. It offers a one-stop solution, from formulation development and packaging to manufacturing.

The firm has a dedicated manufacturing facility, supported by an experienced technical and compliance team, capable of producing tablets, capsules, powders, and liquids in various dosage forms.

Financial Performance (₹ in Crores):

The numbers reflect consistent growth in revenue and profitability, with healthy margins and scalability.

Valuation Metrics:

• EPS (Post-Issue): ₹4.66

• P/E (Post-Issue): ~20.60x

• ROE: 22.16%

• ROCE: 20.48%

• NAV (Pre-Issue): ₹21.02

The IPO is fairly valued when compared with peers in the SME pharma/manufacturing segment.

GMP Today (June 23, 2025):

• Grey Market Premium (GMP): ₹11

• Expected Listing Price: ₹107

• Estimated Listing Gain: ~11.5%

⚠️ Note: GMP is unofficial and speculative in nature. It reflects sentiment but not certainty of actual performance.

Allotment Status:

Allotment can be checked on Maashitla Securities’ website post-June 23:

🔗 https://www.maashitla.com/ipo-allotment-status

Should You Invest?

✅ Strengths:

• Rapid financial growth

• High subscription reflects investor confidence

• Contract manufacturing is an asset-light, scalable model

• Healthy GMP and market buzz

⚠️ Risks:

• SME stocks can be volatile post-listing

• Company is relatively young (est. 2020)

• Healthcare manufacturing space is competitive and regulated

Verdict:

Apply for listing gains if you’re a risk-tolerant investor. Given strong fundamentals, GMP and overwhelming subscription, the IPO shows potential. Long-term investors may also consider holding based on post-listing stability and earnings consistency.

Disclaimer

This article is for educational and informational purposes only. It does not constitute investment advice. IPO investments are subject to market risks, and the Grey Market Premium is not officially regulated. Investors are advised to consult a SEBI-registered financial advisor before investing.

The Upcoming IPOs in this week and coming weeks are Supertech EV, Valencia India, Neetu Yoshi, Abram Food, PRO FX Tech, Suntech Infra Solutions, Shri Hare-Krishna Sponge Iron, Icon Facilitators, Ace Alpha Tech, Globe Civil Projects, Sambhav Steel Tubes, Ellenbarrie Indutrial Gases, Kalpataru, HDB Financials, AJC Jewel.

The Current active IPO are  Aakaar Medical Technologies, Safe Enterprises Retail Fixtures, Mayasheel Ventures.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.